Corrections
offer long term investors entry into pharma stocks: BSE, NSE
In a chat with ET Now, Dipan Mehta,
Member BSE and NSE, shares his views on markets Dipan Mehta, member
. Excerpts:
ET Now: What would you say about the weakness in pharmaceuticals because they too have been a strong leg of the rally so far but again, would you read too much into the way they eased out yesterday?
Dipan Mehta: What we are noticing over the last few months is that the pharmaceutical industry is getting more and more embroiled in some sort of regulatory issues or getting more government attention be it domestically or in the US markets and that is not always a positive step for the industry.
The underlying growth momentum is so strong and the dynamics of the industry as far as Indian exporters are concerned remains so secular that one would have to say that s ..
ET Now: What would you say about the weakness in pharmaceuticals because they too have been a strong leg of the rally so far but again, would you read too much into the way they eased out yesterday?
Dipan Mehta: What we are noticing over the last few months is that the pharmaceutical industry is getting more and more embroiled in some sort of regulatory issues or getting more government attention be it domestically or in the US markets and that is not always a positive step for the industry.
The underlying growth momentum is so strong and the dynamics of the industry as far as Indian exporters are concerned remains so secular that one would have to say that s ..
In the last three-four quarters, the
entire pharma industry has delivered spectacular returns, they have seen huge
outperformance and there is nothing to suggest that these fundamentals have
changed for these companies.
In fact, they are going from strength to strength if you see in terms of number of new filings and new markets other than US which these companies are exploring and what we like the best is that balance sheets over there are in great shape and we have lot of dynamic ma ..
In fact, they are going from strength to strength if you see in terms of number of new filings and new markets other than US which these companies are exploring and what we like the best is that balance sheets over there are in great shape and we have lot of dynamic ma ..
ANAND MAURYA
PGDM-3SEM
Corrections offer long term investors entry into pharma stocks: Dipan Mehta, member BSE, NSE
Read more at:
http://economictimes.indiatimes.com/articleshow/44740562.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
http://economictimes.indiatimes.com/articleshow/44740562.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Corrections offer long term investors entry into pharma stocks: Dipan Mehta, member BSE, NSE
No comments:
Post a Comment